Lv32
330 积分 2023-12-30 加入
Programmed death ligand-1 (PD-L1) clone 22C3 expression in resected colorectal cancer as companion diagnostics for immune checkpoint inhibitor therapy: A comparison study and inter-rater agreement evaluation across proposed cut-offs and predictive (TPS, CPS and IC) scores
1小时前
待确认
Expression and prognostic analysis of three clones of PD-L1 antibody in colorectal cancer
1小时前
求助中
Clinicopathological and prognostic significance of PD-L1 expression in colon adenocarcinoma tumor budding
1小时前
已完结
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
6小时前
已完结
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
22小时前
已完结
Correlation Between Rash and a Positive Drug Response Associated with Bevacizumab in a Patient with Advanced Colorectal Cancer
4天前
已完结
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response
4天前
已完结
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
8天前
已完结
Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with Crizotinib
27天前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
28天前
已完结
皖公网安备34019202002308
